Comparison · NCT01353222-deaths
DN24-02 vs Standard of Care: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DN24-02 vs Standard of Care: deaths from any cause. Trial comparisons, record NCT01353222-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01353222-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.448 | 0.335 | 0.566 | wilson | |
| Risk in group 2 | 0.417 | 0.31 | 0.532 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0311 | -0.13 | 0.191 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.734 | 1.57 | log | |
| Odds ratio, group 1 over group 2 | 1.14 | 0.58 | 2.22 | log | |
| Number needed to harm, for one more death from any cause on DN24-02 than on Standard of Care | 32.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: standard of care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DN24-02 | DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072. | 30 | 67 | EG000 |
| Group 2 | Standard of Care | Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population. | 30 | 72 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse events were collected from the time of registration through investigator-assessed disease recurrence or 30 days following the final infusion of DN24-02, whichever occurred later.
Source ClinicalTrials.gov
Trial
- Title
- DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
- NCT number
- NCT01353222
- Phases
- PHASE2
- Conditions
- Urothelial Carcinoma
- Interventions
- DN24-02, Standard of Care
- Lead sponsor
- Dendreon
- Results first posted
- 2017-05-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01353222?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01353222-deaths